Delta Says Trump's Tariffs Could Impact Millions Of Customers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Delta Air Lines said Thursday that the Trump administration's tariffs could negatively affect millions of customers, Reuters reported.
According to Reuters, the travel giant told the U.S. Commerce Department that in 2023 and 2024, if it hadn't been able to get planes that were made in Canada, Germany and France, it would have been forced to cancel flights impacting as many as 10 million customers.
A "similar impact could be expected going forward" if the Trump administration implements new tariffs affecting the airline, according to Reuters.
A Boeing 757 (757-200) jetliner, belonging to Delta Air Lines, lands at McCarran International Airport in Las Vegas, Nv., on Sun., Feb. 23, 2020.
A Boeing 757 (757-200) jetliner, belonging to Delta Air Lines, lands at McCarran International Airport in Las Vegas, Nv., on Sun., Feb. 23, 2020.
Larry MacDougal via AP
This story is developing and will be updated as more information becomes available.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Morning Movers: GMS Inc. jumps after report of competing suitors
Stock futures are ticking slightly higher as investors digest fresh geopolitical news and continue to weigh the Federal Reserve's latest stance on interest rates. President Trump's announcement of a two-week pause on potential military action against Iran has brought some relief to markets. Brent crude has pulled back to around $77 per barrel as the likelihood of immediate escalation diminishes. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter On the macro side, the Fed's cautious tone earlier this week is still reverberating. Policymakers kept rates unchanged but emphasized that inflation risks remain, tamping down hopes for a September rate cut. Market pricing now sees only a 50%-60% chance of easing by the fall. UBS and other strategists are warning that equity valuations are stretched, and a volatile summer could lie ahead if profit growth or labor data show signs of weakness. For now, investors appear to be in wait-and-see mode heading into the weekend. In pre-market trading, S&P 500 futures are up 0.23%, Nasdaq futures are up 0.32% and Dow futures are up 0.27%. Check out this morning's top movers from around Wall Street, compiled by The Fly. Also check out this morning's Fly By morning movers recap on YouTube. HIGHER – GMS Inc. (GMS) up 28% and QXO (QXO) up 1%, respectively, after The Wall Street Journal reported Home Depot (HD) has made an offer for GMS Inc., kicking off a potential bidding war with QXO, which came public with its own bid on Wednesday EON Resources (EONR) up 1% after entering into a purchase and sale agreement with WPP NM and Northwest Central to acquire all of their respective interests in the South Justis Field located in the Permian Basin in Lea County, New Mexico UP AFTER EARNINGS – CarMax (KMX) up 10% Darden (DRI) up 3% Kroger (KR) up 1% DOWN AFTER EARNINGS – Accenture (ACN) down 5% LOWER – Home Depot (HD) down 1% after reportedly making a competing offer for GMS Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on GMS: Disclaimer & DisclosureReport an Issue Video: Circle extends rally, GMS a major pre-market mover GMS Inc. price target raised to $95 from $71 at Barclays GMS Receives Acquisition Proposal from QXO, Inc. Home Depot bid for GMS may be viewed 'slightly negatively,' says RBC GMS Inc. price target raised to $92.20 from $65 at RBC Capital
Yahoo
an hour ago
- Yahoo
As Tariff Uncertainty Continues, Here Are 2 American Companies Investors Should Consider
Most of President Trump's reciprocal tariffs are currently paused, but that may not last much longer. Tariff uncertainty is significantly lower than it was in April, but it isn't gone. If you're worried about tariff uncertainty, investing in American companies with little exposure can be a good idea. 10 stocks we like better than Berkshire Hathaway › It's been a little over two months since President Trump announced his reciprocal tariff plan, sending the S&P 500 briefly plunging to bear market territory. While the S&P has recovered most of its loss since that point, tariff uncertainty remains. Of course, some of the uncertainty has been resolved, specifically when it comes to our trade relationship with China. But there's a lot we don't know yet, such as what happens when the current 90-day pause on retaliatory tariffs expires on July 8? It's entirely possible that the market will become volatile again because of it. There are very few stocks that are truly immune to tariff uncertainty, but top-quality American companies with little foreign exposure could be a good way to protect your portfolio. With that in mind, here are two great American companies you might want to consider for your portfolio right now. I've said before that if I could only buy one stock to hold for the next 20 years, it would be Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), and I stand by that statement. In fact, with the stock down about 11% from its all-time high reached less than two months ago, I like it even more. There are three main parts to Berkshire's business -- its operating subsidiaries, its stock portfolio, and its cash. Most of Berkshire's operating businesses aren't just American-based revenue streams, but they are highly recession resistant. Think of insurance giant GEICO and Berkshire's massive utility business as a couple of examples. Of course, some of the stocks in Berkshire's nearly $300 billion portfolio have foreign exposure, such as Apple (NASDAQ: AAPL), but it's generally a collection of market-leading businesses with steady cash flow. The cash is the big X-factor here. Berkshire Hathaway has nearly $348 billion in cash on its balance sheet, giving the company unprecedented financial flexibility. So, if tariffs end up causing stocks to fall and business valuations to decline, Berkshire is in a great position to capitalize on it. It's worth noting that the main reason for the stock's recent decline is the announcement that CEO Warren Buffett will be stepping down at the end of the year. But it's important to realize that all of the pieces have been in place for a smooth leadership transition for a long time, and Berkshire should still be an excellent long-term compounding machine. Speaking of Berkshire, it's worth noting that although GEICO is an excellent business, it recently lost its No. 2 market share of U.S. auto insurance to Progressive (NYSE: PGR). Of course, Progressive sells other types of insurance, such as homeowners, but auto insurance is its bread and butter. Although Progressive is often thought of as a legacy insurance company (founded in the 1930s), it has arguably done the most impressive job when it comes to technology and artificial intelligence (AI) in the insurance industry. The company has a first-mover advantage, as it rolled out the first telematics device about 15 years ago to collect driver data and give it an edge in analyzing risk. The company's use of this technology in its underwriting continues to evolve, and the emergence of generative AI has allowed the company to build its technology lead even further. There's still room to grow. In May, Progressive reported 15% year-over-year growth in net premiums earned and a 16% increase in the number of personal insurance policies in force. Progressive's technology lead has not only allowed Progressive to grow its market share but to achieve excellent profitability. In 2024, Progressive reported an underwriting profit margin of more than 11%, while most insurers would be quite content with something in the mid-single digits. As I mentioned, there are few stocks (if any) that would be completely unaffected by tariff escalation. Some of Berkshire's businesses and the stocks it owns have international exposure. And if auto tariffs escalate, it could hurt new car sales, which would have some effect on Progressive (new cars generally cost more to insure than older ones). Not only that, but even if a business is minimally impacted by tariffs, that doesn't mean their stock price won't be turbulent if the trade war heats up. But the point is that these are two fantastic businesses that should hold up better than most if new tariffs go into effect and should be great long-term investments regardless of what happens with tariffs. Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Matt Frankel has positions in Berkshire Hathaway. The Motley Fool has positions in and recommends Apple, Berkshire Hathaway, and Progressive. The Motley Fool has a disclosure policy. As Tariff Uncertainty Continues, Here Are 2 American Companies Investors Should Consider was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Treace Medical Concepts, Inc. (NASDAQ:TMCI) is favoured by institutional owners who hold 53% of the company
Institutions' substantial holdings in Treace Medical Concepts implies that they have significant influence over the company's share price 52% of the business is held by the top 7 shareholders 25% of Treace Medical Concepts is held by insiders Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. If you want to know who really controls Treace Medical Concepts, Inc. (NASDAQ:TMCI), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 53% ownership. Put another way, the group faces the maximum upside potential (or downside risk). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's take a closer look to see what the different types of shareholders can tell us about Treace Medical Concepts. Check out our latest analysis for Treace Medical Concepts Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that Treace Medical Concepts does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Treace Medical Concepts, (below). Of course, keep in mind that there are other factors to consider, too. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It looks like hedge funds own 9.9% of Treace Medical Concepts shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. With a 19% stake, CEO John Treace is the largest shareholder. Armistice Capital LLC is the second largest shareholder owning 9.9% of common stock, and BlackRock, Inc. holds about 6.1% of the company stock. We also observed that the top 7 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Our information suggests that insiders maintain a significant holding in Treace Medical Concepts, Inc.. Insiders own US$86m worth of shares in the US$343m company. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently. The general public-- including retail investors -- own 12% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Treace Medical Concepts you should know about. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
